Cannell & Co’s Annovis Bio ANVS Stock Holding History

Cannell & Co’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$187K	Hold	10,000	–	–	0.01%	256
2023 Q3	$94.9K	Hold	10,000	–	–	﹤0.01%	252
2023 Q2	$143K	Hold	10,000	–	–	﹤0.01%	251
2023 Q1	$154K	Hold	10,000	–	–	0.01%	256
2022 Q4	$134K	Hold	10,000	–	–	﹤0.01%	246
2022 Q3	$137K	Hold	10,000	–	–	0.01%	248
2022 Q2	$113K	Hold	10,000	–	–	﹤0.01%	257
2022 Q1	$134K	Hold	10,000	–	–	﹤0.01%	270
2021 Q4	$176K	Sell	10,000 -6,200	-38%	-$160K	0.01%	275
2021 Q3	$514K	Buy	16,200 +200	+1%	+$11.5K	0.02%	216
2021 Q2	$1.37M	Buy	16,000 +6,000	+60%	+$277K	0.04%	169
2021 Q1	$279K	Hold	10,000	–	–	0.01%	251
2020 Q4	$75K	Hold	10,000	–	–	﹤0.01%	266
2020 Q3	$48K	Hold	10,000	–	–	﹤0.01%	245
2020 Q2	$44K	Hold	10,000	–	–	﹤0.01%	241
2020 Q1	$30K	Buy	+10,000	New	+$49.2K	﹤0.01%	229

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cannell & Co's ANVS Position: Q4 2023 in Review

Cannell & Co held its Annovis Bio (ANVS) position steady in Q4 2023 at 10,000 shares worth $187K. The position accounts for 0.01% of the portfolio, ranked #256.

Cannell & Co first reported a position in ANVS in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.37M in Q2 2021. 36 funds tracked by Wall St. Rank hold ANVS as of Q4 2023.

Cannell & Co held 10,000 shares of Annovis Bio worth $187K as of Q4 2023.
Cannell & Co left its Annovis Bio share count unchanged in Q4 2023.
Annovis Bio made up 0.01% of Cannell & Co's portfolio in Q4 2023, its #256 holding.
Cannell & Co first reported a position in Annovis Bio in Q1 2020 and has held it in 16 quarters since.
Cannell & Co's Annovis Bio position peaked at $1.37M in Q2 2021.
36 funds tracked by Wall St. Rank held Annovis Bio as of Q4 2023.

Based on Cannell & Co's 13F filing for Q4 2023, filed 5 Feb 2024.